Cancer investigation · 2026
Tumor Lysis Syndrome in Solid Tumors: An Emerging Oncologic Emergency in the Era of Precision Oncology.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okabayashi Takehiro, Inada Ryo, Tabuchi Motoyasu, Takata Nobuo, Mimura Naoki
Аннотация
BACKGROUND: Tumor lysis syndrome (TLS), traditionally linked to hematologic malignancies, is increasingly recognized in solid tumors due to highly effective precision therapies.
AIM: This review evaluates solid-tumor TLS epidemiology, pathophysiology, and risk-adapted management.
RESULTS: While uncommon, solid-tumor TLS incidence is rising. Major risk factors include high tumor burden, extensive liver metastases, and renal dysfunction. Reports are increasing in gastrointestinal malignancies. Advanced targeted therapies and immunotherapies make treatment responsiveness a critical risk determinant.
CONCLUSION: Integrating molecular biomarkers and treatment-related factors into risk stratification is essential for precision supportive care to optimize solid-tumor patient outcomes.
AIM: This review evaluates solid-tumor TLS epidemiology, pathophysiology, and risk-adapted management.
RESULTS: While uncommon, solid-tumor TLS incidence is rising. Major risk factors include high tumor burden, extensive liver metastases, and renal dysfunction. Reports are increasing in gastrointestinal malignancies. Advanced targeted therapies and immunotherapies make treatment responsiveness a critical risk determinant.
CONCLUSION: Integrating molecular biomarkers and treatment-related factors into risk stratification is essential for precision supportive care to optimize solid-tumor patient outcomes.